Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 38OTHER 30NETWORK 19INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

Erlotinib Hydrochloride 2exatecan 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Familial ependymoma × Clear all
NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated
25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Astellas Pharma Inc

Phase 2 Terminated
4 enrolled 9 charts

Familial ependymoma, Ependymoma

NCT00004212 2012-05-16

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Daiichi Sankyo

Phase 1 Completed
CNSLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Lymphoma, Medulloblastoma, Oligodendroglioma, Recurrence, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡